Amgen Inc (AMGN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Amgen ( AMGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.2%. By the end of trading, Amgen rose $5.12 (4.3%) to $124.37 on heavy volume. Throughout the day, 5,025,885 shares of Amgen exchanged hands as compared to its average daily volume of 2,980,900 shares. The stock ranged in a price between $119.58-$124.46 after having opened the day at $119.83 as compared to the previous trading day's close of $119.25. Other companies within the Drugs industry that increased today were: Mast Therapeutics ( MSTX), up 43.2%, DARA Biosciences ( DARA), up 21.6%, Atossa Genetics ( ATOS), up 18.0% and Evoke Pharma ( EVOK), up 17.3%.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $89.9 billion and is part of the health care sector. The company has a P/E ratio of 18.9, above the S&P 500 P/E ratio of 17.7. Shares are up 4.4% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the negative front, Ocera Therapeutics ( OCRX), down 12.4%, ImmunoCellular Therapeutics ( IMUC), down 9.7%, iBio ( IBIO), down 9.4% and Coronado Biosciences ( CNDO), down 7.9% , were all laggards within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback